CoChat

Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease

Open access
Montani, D., Jaïs, X., Price, L. C., Achouh, L., Degano, B., Mercier, O., Mussot, S., Fadel, E., Dartevelle, P., Sitbon, O., Simonneau, G., Humbert, M. · 2009 · European Respiratory Journal
Cited by 106

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Pulmonary veno-occlusive disease (PVOD) carries a poor prognosis and lung transplantation is the only curative treatment. In PVOD, epoprostenol therapy is controversial, as this condition may be refractory to specific therapy with an increased risk of pulmonary oedema. We retrospectively reviewed clinical, functional and haemodynamic data of 12 patients with PVOD (10 with histological confirmation) treated with continuous intravenous epoprostenol and priority listed for lung transplantation after January 1, 2003. All PVOD patients had severe clinical, functional and haemodynamic impairment at presentation. Epoprostenol was used at low dose ranges with slow dose increases and high dose diuretics. Only one patient developed mild reversible pulmonary oedema. After 3–4 months, improvements were seen in the New York Heart Association functional class (class IV to III in seven patients), cardiac index (1.99±0.68 to 2.94±0.89 L·min −1 ·m −2 ) and indexed pulmonary vascular resistance (28.4±8.4 to 17±5.2 Wood units·m −2 ; all p<0.01). A nonsignificant improvement in the 6-min walk distance was also observed (+41 m, p = 0.11). Two patients died, one patient was alive on the transplantation waiting list on December 1, 2008 and nine patients were transplanted. Cautious use of continuous intravenous epoprostenol improved clinical and haemodynamic parameters in PVOD patients at 3–4 months without commonly causing pulmonary oedema, and may be a useful bridge to urgent lung transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00017809

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 106

Metadata

Authors
Montani, D., Jaïs, X., Price, L. C., Achouh, L., Degano, B., Mercier, O., Mussot, S., Fadel, E., Dartevelle, P., Sitbon, O., Simonneau, G., & Humbert, M.
Venue
European Respiratory Journal
Published
2009-06-18
Volume
34
Issue
6
Pages
1348-1356
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2150226364
Cited by
106
References
2
FWCI
7.62
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. https://app.cochat.ai/papers/10.1183/09031936.00017809
The paper
Montani, D., Jaïs, X., Price, L. C., Achouh, L., Degano, B., Mercier, O., Mussot, S., Fadel, E., Dartevelle, P., Sitbon, O., Simonneau, G., & Humbert, M. (2009). Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. European Respiratory Journal. https://doi.org/10.1183/09031936.00017809

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.